Xolair vs Fasenra
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Xolair | US Fasenra | |
|---|---|---|
| Generic name | omalizumab | benralizumab |
| Drug class | Anti-IgE Monoclonal Antibody | IL-5 Receptor Antagonist (Biologic) |
| Treats | Allergic asthma, chronic hives, food allergy | Severe eosinophilic asthma |
| Category | Respiratory | Respiratory |
| Manufacturer | Genentech/Novartis | AstraZeneca |
| Year approved | 2003 | 2017 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $95M | $80M |
| Common side effects | Anaphylaxis (severe allergic reaction), Injection site reactions, Joint pain, Headache | Headache, Sore throat, Allergic reactions, Injection site reactions |
Frequently asked questions
Is Xolair or Fasenra better?
Neither is universally "better." Xolair (omalizumab) and Fasenra (benralizumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xolair and Fasenra?
Xolair is a Anti-IgE Monoclonal Antibody made by Genentech/Novartis, while Fasenra is a IL-5 Receptor Antagonist (Biologic) made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xolair has the larger estimated TV advertising budget of the two.